Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Net Cash Flow (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Net Cash Flow data on record, last reported at -$9.4 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 179.38% year-over-year to -$9.4 million; the TTM value through Sep 2025 reached -$12.0 million, up 36.51%, while the annual FY2024 figure was -$1.2 million, 97.82% up from the prior year.
  • Net Cash Flow reached -$9.4 million in Q3 2025 per SGMO's latest filing, down from $10.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $46.8 million in Q2 2021 and bottomed at -$58.8 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$5.6 million, with a median of -$8.0 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: crashed 633.08% in 2022, then soared 220.71% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $2.0 million in 2021, then surged by 150.81% to $5.1 million in 2022, then tumbled by 348.34% to -$12.7 million in 2023, then skyrocketed by 139.2% to $5.0 million in 2024, then crashed by 288.52% to -$9.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$9.4 million in Q3 2025, $10.4 million in Q2 2025, and -$18.0 million in Q1 2025.